Paper10408384
C1-inhibitor attenuates hyperacute rejection and inhibits complement, leukocyte and platelet activation in an ex vivo pig-to-human perfusion model.
Fiane AE and 5 others. Immunopharmacology, 1999. Cited by 54 papers, by iCite.
Cite this record
ConductScience Library. C1-inhibitor attenuates hyperacute rejection and inhibits complement, leukocyte and platelet activation in an ex vivo pig-to-human perfusion model. Papers, record 10408384. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/10408384
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- C1-inhibitor attenuates hyperacute rejection and inhibits complement, leukocyte and platelet activation in an ex vivo pig-to-human perfusion model.
- PubMed
Topics24
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Complement C1 Inactivator Proteins | Major topic |
| Complement Pathway, Classical | Major topic |
| Graft Rejection | Major topic |
| Kidney Transplantation | Major topic |
| Leukocytes | Major topic |
| Platelet Activation | Major topic |
| Transplantation, Heterologous | Major topic |
| Animals | |
| Antigens | |
| Complement C1 | |
| Complement C3b | |
| Female | |
| Graft Survival | |
| Humans | |
| Immunoblotting | |
| Immunohistochemistry | |
| Kidney | |
| Kininogens | |
| Lymphocyte Activation | |
| Male | |
| Neutrophil Activation | |
| Perfusion | |
| Prekallikrein | |
| Swine |
Source PubMed
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 54 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40589132 | Immunosuppressive and Non-Immunosuppressive Drugs for Heart Xenotransplantation in Humans: Is Europe Ready? | Xenotransplantation | 2025 | https://conductscience.org/library/papers/40589132 | PubMed |
| 37548030 | Antibody-mediated rejection in xenotransplantation: Can it be prevented or reversed? | Xenotransplantation | 2023 | https://conductscience.org/library/papers/37548030 | PubMed |
| 32155167 | Normothermic machine perfusion of ischaemically damaged porcine kidneys with autologous, allogeneic porcine and human red blood cells. | PLoS One | 2020 | https://conductscience.org/library/papers/32155167 | PubMed |
| 30882931 | Knockdown of circulating C1 inhibitor induces neurovascular impairment, glial cell activation, neuroinflammation, and behavioral deficits. | Glia | 2019 | https://conductscience.org/library/papers/30882931 | PubMed |
| 29935708 | Innate networking: Thrombotic microangiopathy, the activation of coagulation and complement in the sensitized kidney transplant recipient. | Transplant Rev (Orlando) | 2018 | https://conductscience.org/library/papers/29935708 | PubMed |
| 27554374 | Generation of α-1,3-galactosyltransferase knocked-out transgenic cloned pigs with knocked-in five human genes. | Transgenic Res | 2017 | https://conductscience.org/library/papers/27554374 | PubMed |
| 27500225 | Kidneys From α1,3-Galactosyltransferase Knockout/Human Heme Oxygenase-1/Human A20 Transgenic Pigs Are Protected From Rejection During Ex Vivo Perfusion With Human Blood. | Transplant Direct | 2015 | https://conductscience.org/library/papers/27500225 | PubMed |
| 25249935 | C1-Inhibitor protects from focal brain trauma in a cortical cryolesion mice model by reducing thrombo-inflammation. | Front Cell Neurosci | 2014 | https://conductscience.org/library/papers/25249935 | PubMed |
| 21496117 | Absence of Gal epitope prolongs survival of swine lungs in an ex vivo model of hyperacute rejection. | Xenotransplantation | 2011 | https://conductscience.org/library/papers/21496117 | PubMed |
| 21345278 | Bench-to-bedside review: the role of C1-esterase inhibitor in sepsis and other critical illnesses. | Crit Care | 2011 | https://conductscience.org/library/papers/21345278 | PubMed |
| 19710096 | Anti-inflammatory effects of C1-Inhibitor in porcine and human whole blood are independent of its protease inhibition activity. | Innate Immun | 2010 | https://conductscience.org/library/papers/19710096 | PubMed |
| 19376229 | Antibody-mediated xenograft injury: mechanisms and protective strategies. | Transpl Immunol | 2009 | https://conductscience.org/library/papers/19376229 | PubMed |
| 18674818 | Biological activities of C1 inhibitor. | Mol Immunol | 2008 | https://conductscience.org/library/papers/18674818 | PubMed |
| 17544816 | C1 inhibitor: biologic activities that are independent of protease inhibition. | Immunobiology | 2007 | https://conductscience.org/library/papers/17544816 | PubMed |
| 11737055 | Endothelial targeting with C1-inhibitor reduces complement activation in vitro and during ex vivo reperfusion of pig liver. | Clin Exp Immunol | 2001 | https://conductscience.org/library/papers/11737055 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| SERPING1 | 710 | PubTator's text mining | https://conductscience.org/library/genes/710 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/10408384
GET https://conductscience.org/api/papers/v1/10408384/authors